Form 4: 10x Genomics CFO Sells Shares to Cover Tax Obligations
Insider Transaction Report
Adam Taich, Chief Financial Officer of 10x Genomics, Inc., sold 4,044 shares of Class A Common Stock for tax withholding purposes related to restricted stock unit vesting.
Summary
- Adam Taich, the Chief Financial Officer of 10x Genomics, Inc. (TXG), reported a transaction involving the company's Class A Common Stock.
- On May 22, 2025, Mr. Taich disposed of 4,044 shares of Class A Common Stock.
- The shares were sold at a price of $8.2993 per share.
- The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following this transaction, Mr. Taich beneficially owns 331,588 shares of Class A Common Stock directly.
Sentiment
Score: 5
Explanation: The transaction is a routine sale to cover tax obligations from RSU vesting, which is a neutral event and does not reflect a discretionary decision by management regarding the company's future prospects. Therefore, it has a neutral impact on sentiment.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Management Comments
- The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically a sale to cover tax obligations, which is common for executives receiving equity compensation. It does not provide insights into broader industry trends or competitive landscape within the life sciences or genomics sector.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive for tax purposes is a routine event and typically has minimal direct impact on existing shareholders, as it is not a discretionary sale based on company performance outlook.
Key Dates
| Date | Description |
|---|---|
| 05/22/2025 | Date of transaction (sale of shares). |
| 05/27/2025 | Date the Form 4 was signed by Eric S. Whitaker, as Attorney-in-Fact for Adam Taich. |
Keywords
10x Genomics, TXG, Adam Taich, CFO, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.